Amrita Krishnan, MD
Enriched profileNason-Hollingsworth Endowed Chair for Multiple Myeloma; Executive Medical Director of Hematology, City of Hope Orange County; Chair, SWOG Barlogie-Salmon Myeloma Committee (as of Nov 1, 2025) · City of Hope
Amrita Krishnan is Nason-Hollingsworth Endowed Chair for Multiple Myeloma; Executive Medical Director of Hematology, City of Hope Orange County; Chair, SWOG Barlogie-Salmon Myeloma Committee (as of Nov 1, 2025) at City of Hope. ClinicalTrials.gov lists 14 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 2 Sept 2026
Amrita Krishnan, MD, is Nason-Hollingsworth Endowed Chair for Multiple Myeloma at City of Hope (Orange County Lennar Foundation Cancer Center / Briskin Center for Multiple Myeloma Research, Duarte). It also documents an investigator role on 14 registered clinical trials, industry payments reported by 22 companies, 1 NIH-funded awards (1999–2009).
- Top research focus: Hematology
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 2 Sept 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor: SWOG Cancer Research Network
- Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Sponsor: City of Hope Medical Center
Industry payments
Updated 2 Sept 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments$49,305openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20256 payments$28,327openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202510 payments$10,181openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
99.6%CD38-directed Cytolytic Antibody99.6%Daratumumab100%Part B, office-administered≥16 patientsDermatology
0.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.3%Acyclovir100%Part D<11 patientsMetabolism & gastrointestinal
0.1%Serotonin-3 Receptor Antagonist0.1%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 2 Sept 2026
1 NIH research award on record, funded 1999–2009 per NIH RePORTER. The latest:
- PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS
University of Southern California
FY2009$7,569M01RR000043 - CLINICAL TRIAL: A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL
University of Southern California
FY2008$1,201M01RR000043 - A PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS
University of Southern California
FY2008$1,106M01RR000043
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.
Journal of Clinical Oncology
2024 - Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
New England Journal of Medicine
2022
Online presence
Updated 2 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/amrita-krishnan-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Doximity
doximity.com/pub/amrita-krishnan-md-cf4a7f71
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - X / Twitter
x.com/DoctorAKrishnan
Mentions by others
where others cite or feature them- Spotify
creators.spotify.com/pod/profile/astct/episodes/Bispecific-Antibodies-in-Myeloma-The-Who--What--When--and-Where-e22k717
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →creators.spotify.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 2 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
- Internal Medicine residency
Strong Memorial Hospital, University of Rochester
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗ - Hematology/Oncology fellowship
Beth Israel Deaconess Medical Center / Harvard Medical School (also City of Hope, Dana-Farber Cancer Institute per secondary source)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗ - Board Certified
American Board of Internal Medicine, Hematology (ABMS)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗ - B.S.
Union College, Schenectady, NY (Cum Laude, Phi Beta Kappa)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercenter.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →swog.org ↗
- Chair
SWOG S1803 DRAMMATIC study (Phase 3, post-transplant maintenance in myeloma)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →swog.org ↗ - Director
City of Hope Judy and Bernard Briskin Center for Multiple Myeloma Research (past decade per SWOG bio)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →swog.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercenter.com ↗
- Phi Beta Kappa and Cum Laude graduate
Union College (Schenectady, NY), B.S.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercenter.com ↗
Secondary affiliations
appointments beyond the home institution- Clinical Advisor
Sutro Biopharma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗ - Faculty
City of Hope Comprehensive Cancer Center Hematologic Malignancies Program
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗
Media & interviews
press, podcasts and appearances- VJHemOnc
multiple video interviews on myeloma treatment (e.g., 'Sequencing of BCMA-directed therapies for multiple myeloma')
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - OncLive
recurring contributing author/interviewee on multiple myeloma coverage
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - TargetedOnc
video interview 'Key Innovations and Ongoing Challenges in Multiple Myeloma Treatment'
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hope Rugo, MD
City of Hope
James Ito, MD
City of Hope
Victoria Seewaldt
City of Hope
Dean Lim, MD
City of Hope